Clinical context
Cataract surgery outcomes are not defined by best-corrected visual acuity alone. Refractive accuracy, vision at different distances, spectacle dependence, contrast sensitivity, dysphotopsia and procedural safety all matter. Corneal and macular status, capsular support, cataract density and IOL calculation also shape the final result. A statistically convincing average therefore still has to be interpreted against the characteristics of an individual eye.
What was studied
This retrospective study included 164 eyes of 131 patients with axial length above 26 mm after uncomplicated cataract surgery with a monofocal IOL. Biometry used the IOLMaster 700. Barrett Universal II, SRK/T, Haigis, Holladay I, Holladay II and Hoffer Q were compared using absolute and numerical errors and proportions within refractive thresholds from ±0.25 to ±2.00 D.
How the evidence was produced
A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.
How to interpret the result
In long eyes, small biometric and modeling errors can produce a meaningful refractive miss. Barrett Universal II had the best numerical result, but the data do not support universal superiority over SRK/T or Haigis. Even with the leading formula, about 41% of eyes missed ±0.50 D, so expectations should remain realistic and lens constants should be optimized.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
This evidence is most useful as a basis for preoperative discussion and surgical planning. It helps identify which outcomes should be measured and which trade-offs should be explained to patients. The average effect should not be generalized to every IOL, technique or patient without checking eligibility criteria, surgeon experience, biometry, ocular comorbidity and duration of follow-up.
Limitations
These were retrospective data from one tertiary center in 2018–2021. Both eyes from some patients may have been included, requiring appropriate handling of correlated observations. Kane, EVO, Hill-RBF and Pearl-DGS were not tested. Results depend on the biometer, IOL model, constant optimization and distribution of very long eyes. They do not establish equal performance in every axial-length interval.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.